atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.

Details of the company's participation:

Format: Fireside Chat
Date and Time: Thursday June 6 at 10:00 A.M. ET
Location: New York
Webcast link: here

The live webcast of the fireside chat will also be available on the Investors section of the atai website under Events . A replay will be available following the live event.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life .

Contact Information

Investor Contact:

IR@atai.life

Media Contact:

PR@atai.life


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATAI:US
The Conversation (0)
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements.

Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operating Officer at Pacira Pharmaceuticals, Inc. and portfolio manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group, earning his medical degree from the Albert Einstein College of Medicine and his undergraduate degree from Cornell University.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

  • First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H'24; Phase 2 study in TRD patients anticipated to initiate around YE'24
  • Beckley Psytech's Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H'24
  • Compass Pathways' Phase 2 study of COMP360 in PTSD patients demonstrated durable improvement in symptoms; Phase 3 data of COMP360 in TRD patients expected in 4Q'24
  • Co-Founder Florian Brand to step down as CEO as part of a planned transition by YE'24 and to be succeeded by Co-Founder and current Chief Scientific Officer Srinivas Rao, M.D., Ph.D.
  • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced first quarter 2024 financial results, provided corporate updates and announced a transition in its leadership.

Florian Brand ("Mr. Brand"), Co-Founder and current CEO, will step down as CEO by the end of this year. Co-Founder Srinivas Rao, M.D., Ph.D. ("Dr. Rao"), currently the Chief Scientific Officer, will be promoted to Co-CEO effective June 1, 2024 and intends to assume the role of CEO by the end of the year subject to appointment as required by local law.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

  • The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.
  • Initial results from   the   recently completed   monotherapy   Part 1 of the study   were   shared in March 2024   ,   and   showed that a single dose of BPL-003 was safe and well-tolerated, with a rapid and durable antidepressant effect lasting up to   12-weeks   post-dose.
  • Part 2 of the study will investigate a single dose of BPL-003 in patients who are currently on a course of SSRI antidepressants.
  • The first patient has been dosed in Part 2 of the study and initial results are expected in H1 2025.

Atai Life Sciences (NASDAQ: ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech's Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Resistant Depression (TRD).

In Part 2 of this open-label Phase 2a study ( NCT05660642 ), patients with moderate-to-severe TRD who are on a stable course of certain oral selective serotonin reuptake inhibitor (SSRI) antidepressants will receive a single dose of BPL-003 alongside psychological support to explore the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BPL-003 as an adjunctive therapy to SSRIs. Patients will be followed for 12 weeks post-dosing. Initial results are expected in H1 2025.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×